PER 34.1% 8.9¢ percheron therapeutics limited

antisense technology, page-15

  1. 4,693 Posts.
    lightbulb Created with Sketch. 720
    Personally and my medical knowledge stops at band-aid application, I reckon the newsletter reads pretty solid, but ANP remains a long-term play. In the current market, nothing short of a big deal done will drive any share up! ANP is my next MSB, which I believe in turn will be the next CSL - there my big UNprofessional calls, but you gotta have faith and a long-time horizon!

    DYOR.

    ;)


 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.